More than semen analysis
Fellow is a high-complexity mail-in semen analysis lab and the largest dedicated semen analysis facility in the U.S., with more than 225,000 samples analyzed to date. Our clinically validated mail-in process¹ accounts for semen degradation over time—making it the only mail-in test proven to match the accuracy of a traditional 1-hour analysis.
Our Investors Include
Newsflash: Patients don't want to produce a semen sample in public.
Fellow was founded in 2018 with the simple goal of making semen analysis accessible, comfortable, and easy to understand. Once our clinical validation was published in Fertility & Sterility in 2021¹, we were able to offer the only diagnostic-grade mail-in semen analysis on the market. We have now help thousands of U.S. urology and fertility clinics improve lab economics, reduce risk, expand access to testing, and drive patient conversions to treatment—with new customers added all the time.
Fellow is pioneering the semen-based diagnostics of the future.
Powered by expert scientific leadership, and in partnership with clinics and academic institutions nationwide, our vision for the future of semen-based diagnostics is already taking shape. In groundbreaking research, we have demonstrated that seminal plasma is rich in cell free DNA (cfDNA) from somatic cells, and provided new insights into its potential as a liquid biopsy for several conditions. Furthermore, we've shown that biomarkers in seminal fluid can differentiate clinically significant prostate cancer (Grade Group 2+) from indolent cancer or no cancer.
Meet our team
Industry leaders drive our commercial, clinical, and research expertise. With leadership firmly in place, our commercial and R&D programs are well-established and poised for transformation.
Fellow achieved a significant milestone of delivering more than 100,000 patient test results since its product launch in 2020.
Fellow announced reserach findings demonstrating that its mail-in postvasectomy semen analysis (PVSA) kits significantly improve compliance rates.
Fellow announced research showing that seminal plasma is a rich source of cell free DNA from somatic cells and provides new insights into its potential as a liquid biopsy.
Fellow presented studies highlighting mail-in semen analysis as a potential post-PSA reflex test as well as an alternative to in-clinic post-vasectomy semen analysis (PVSA).
Fellow Health announced today the close of a $24 million Series B financing round led by 5AM Ventures, with new participation from The Forest Road Company.
Learn more about…
3,000+ clinics trust Fellow.
Samplaski et al. Development and validation of a novel mail-in semen analysis system and the correlation between one hour and delayed semen analysis testing; Fertil Steril. 2021;115(4):922-929
